Aktienanalyse zu Gilead Sciences, Inc (GILD)GILDGilead Sciences, Inc

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Gilead Sciences Inc is a good buy right now due to its current price of $156.04, which is below the analyst price target range of $126 to $170. The company has shown a strong financial performance with a 10% year-over-year revenue increase to $7.8 billion in the last quarter, and a solid gross margin of 79.76%. However, investors should be cautious of the recent net income drop to -10.5 billion in Q2 2026, which poses a risk to future profitability.

28 analysts cover GILD: 13 rate it Buy, 15 Hold and 0 Sell. The average price target is 137.88.